Top Suppliers:I want be here
Related CAS#:
1251686-20-0 1286705-66-5
1251576-53-0 1251559-88-2
1251543-03-9 1251610-29-3
1251686-21-1 1251632-57-1
1251564-48-3 1251575-91-3

1166254-80-3

1166254-80-3 structure
1166254-80-3 structure
  • Name: Voxvoganan
  • Chemical Name: ltx-109
  • CAS Number: 1166254-80-3
  • Molecular Formula: C43H69N11O3
  • Molecular Weight: 788.08000
  • Catalog: Signaling Pathways Anti-infection Bacterial
  • Create Date: 2017-03-08 04:55:26
  • Modify Date: 2025-08-25 14:46:40
  • Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA[1][2].
Name ltx-109
Synonyms Lytixar
(2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
UNII-HO813QDF65
Description Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA[1][2].
Related Catalog
In Vitro Voxvoganan (LTX-109) is an investigational antimicrobial agent with a membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. Voxvoganan has a rapid bactericidal lytic activity. Voxvoganan demonstrates in vitro bactericidal activity against a number of S. aureus isolates resistant to several classes of antimicrobial agents evaluated in this study[2]. Voxvoganan (LTX-109) is a broad-spectrum, fast-acting bactericidal antimicrobial agent that binds to negatively charged membrane components on the bacterial cell wall, which leads to membrane disruption and cell lysis. Voxvoganan is a first-in-class chemically synthesized, small peptide drug that is stable against protease degradation. Topical application of Voxvoganan has a good safety profile and a low bioavailability. Voxvoganan demonstrates good activity against Staphylococcus aureus strains that are susceptible and resistant to mupirocin[3].
References

[1]. Johan Isaksson, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.

[2]. Louis D Saravolatz, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82.

[3]. L D Saravolatz, et al. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates. Lett Appl Microbiol. 2017 Nov;65(5):410-413.
Molecular Formula C43H69N11O3
Molecular Weight 788.08000
Exact Mass 787.55800
PSA 263.38000
LogP 9.38830
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:1166254-80-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1166254-80-3 | Chemsrc address: https://m.chemsrc.com/en/baike/309970.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved